Disclosure filings reveal that U.S. Representative Kevin Hern sold his entire stake in UnitedHealth Group on December 23, 2025, in a single transaction valued between $250,001 and $500,000. The sale was reported on January 22, 2026, and marked as a full exit, occurring after UnitedHealth’s shares hit recent lows following a volatile 2025. Hern’s position had been built over 12 purchases between October 2021 and July 2024 while he served on the House Ways and Means Subcommittee on Health, overseeing policies that directly affect Medicare and Medicaid insurers.

Since Representative Hern’s exit, UnitedHealth’s shares have risen more than 9%, outperforming major market indices over the same period. The insurer’s 2025 downturn was driven by rising medical costs within its Medicare Advantage business, margin compression, regulatory scrutiny and abrupt management changes that led to multiple forecast cuts. Investors are now debating whether the full sale at year-end reflected poor timing, loss-limiting strategy or policy expectations that failed to materialize.

The Federal Trade Commission has stayed its administrative case against UnitedHealth’s OptumRx unit, delaying the evidentiary hearing until July 1, 2026. Originally filed in September 2024, the lawsuit accuses pharmacy benefit managers of practices that inflated insulin prices through rebate structures and markups. The 14-day suspension, approved January 20, halts all discovery and filing deadlines, and follows intensifying scrutiny from a 2025 FTC staff report on specialty drug markups and new investigative reporting on PBM profit-obscuring tactics.